ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / GRI / earnings
ERNA (33) ONCO (30) CVKD (32) EOCN (36) ⌘ Pro Terminal →

GRI Bio Inc. (GRI) Next Earnings Date & Expected ±12.5% Move

$1.53 -2.55% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.52

GRI Bio Inc. (GRI) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D- • RED ALERT Cap $3.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GRI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GRI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, GRI Bio Inc. (NASDAQ: GRI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.53 (-2.55% 1D, market cap $3.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GRI compare to ERNA and ONCO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GRI carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ERNA (Ernexa Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M) and ONCO (Onconetix Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M). Among the 5-stock peer group, GRI leads on earnings multiple (N/A) while GRI leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GRI?
▼

Per GRI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001824293), GRI Bio Inc. generated $0 in revenue, -$12.0M in net income, and -$10.2M in free cash flow against $8.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.52 (-0.65%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (8)Whales (5)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.2% Base Target
$67 Bull$1 Base$1 Bear
📬 FREE GRI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GRI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY GRI SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (24% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 46.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
45
Grade D$1.57-7.6% Next Q
Q2 (-2Q)
42
Grade D$1.45+3.4% Next Q
Q3 (-1Q)
40
Grade D$1.50+2% Next Q
Current
37
Grade D-$1.53-8.1% Hist 90D α
Trajectory: D (45) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GRI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GRI currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.82) and Max Pain ($1.61) forces dealer call-delta covering toward $67.33.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GRI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GRI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.19 Expected Swing
$1.34 (-12.5%)Spot $1.53$1.72 (+12.5%)
MODEL EARNINGS SETUP GAUGE

GRI Quantitative Pre-Earnings Setup: 37/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (37/100)Model Risk Weight (63/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$0-$12.0M-$10.2M52%
FY 20242024-12-31$0-$8.2M-$8.6M52%
FY 20232023-12-31$0-$13.0M-$9.0M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GRI)

  • ✓Walkthrough of GRI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
GRI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -32.30%🛡️ HOLDING TREND SUPPORT
2026-11-02O $1.62H $1.62L $1.53C $1.53VOL 23.1K
RES: $3.82SUP: $1.36SMA50: $1.82SMA200: $2.21
$29.02$21.52$14.03$6.53$-0.97RES $3.82SUP $1.36$1.532026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GRI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GRI Butterfly Map → + Track GRI →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GRI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GRI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GRI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GRI)

Health Care Rank #623 of 1016 ⚔️ ERNA vs GRI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GRI vs. ERNA, ONCO, CVKD, EOCN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, GRI Bio Inc. (GRI) ranks #623 by composite RQD confidence (37/100, grade D-) and #973 by equity capitalization ($3.4M). Within this direct 5-issuer industry benchmark cohort, GRI leads on earnings valuation at N/A trailing P/E, while GRI leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GRI currently leads its immediate peer cohort in composite quantitative strength at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GRI ACTIVE
GRI Bio Inc.
D- 37/100 — — -35.0% -2.55% $3.4M Benchmark Subject
ERNA
Ernexa Therapeutics Inc.
E 33/100 — — -35.0% -6.63% $3.4M /erna-vs-gri →
ONCO
Onconetix Inc.
E 30/100 — 77.6% -35.0% -4.27% $3.5M /onco-vs-gri →
CVKD
Cadrenal Therapeutics Inc.
E 32/100 — — -35.0% +4.41% $3.4M /cvkd-vs-gri →
EOCN
Eocene Ltd.
D- 36/100 — — -35.0% -3.73% $3.4M /eocn-vs-gri →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001824293

In its most recent audited fiscal period (FY2025, filed 2025-12-31), GRI Bio Inc. (GRI) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$12.0M, operating cash flow of -$10.2M, and free cash flow of -$10.2M (-18.3% YoY). On the balance sheet, GRI closed FY2025 with $8.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$12.0M -$10.2M -$10.2M $8.7M —
FY2024 (FY) 2024-12-31 $0 -$8.2M -$8.6M -$8.6M $5.7M —
FY2023 (FY) 2023-12-31 $0 -$13.0M -$9.0M -$9.0M — —

3. GRI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GRI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, GRI Bio Inc. (NASDAQ: GRI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.53 (-2.55% 1D, market cap $3.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

How does GRI compare to ERNA and ONCO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GRI carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ERNA (Ernexa Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M) and ONCO (Onconetix Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M). Among the 5-stock peer group, GRI leads on earnings multiple (N/A) while GRI leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GRI?

Per GRI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001824293), GRI Bio Inc. generated $0 in revenue, -$12.0M in net income, and -$10.2M in free cash flow against $8.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GRI trading relative to its 50-day, 200-day, and 52-week technical levels?

GRI last traded at $1.53 (-2.55% on volume of 28,780 shares), positioning the stock -15.93% below its 50-day simple moving average ($1.82) and -30.77% below its 200-day simple moving average ($2.21). Across its 52-week range of $1.36 to $64.12, GRI sits at the 0.3% percentile with a 14-day RSI of 46.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.34 to $1.72).

GRI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is GRI's next earnings date?

Based on SEC filing cadence, GRI Bio Inc. (GRI)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is GRI stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for GRI, spanning a range between $1.34 and $1.72.

Direct Sub-Reports: GRI RQD Cockpit GRI 12M Forecast GRI Earnings & Move GRI Dividends & DRIP GRI Insiders & 13F GRI Whale Options GRI Profit Sankey GRI News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

GRI — GRI Bio Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:54:01Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 37 out of 100, a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow" (per the Roarable RQD rating). The five pillars are scored as follows (per the Roarable RQD rating):

  • Fundamental Cash Engine: 8 / 20. The source cites ROIC of -35% and FCF yield of 0%. For a prospective investor, this indicates the business is not currently generating returns on invested capital or free cash flow from operations.
  • Whale 13F Flow: 5 / 20. Scored on institutional accumulation and options positioning. The source does not provide holder-level detail (see Analyst View section), so the low score reflects the rating methodology's read of available flow data.
  • Insider Conviction: 5 / 20. Scored on SEC Form 4 and Congressional PTR cluster flow. No insider transaction detail is supplied in the source data.
  • Macro Regime Fit: 9 / 20. The source lists Beta of 1.0 and notes sector sensitivity. A prospective investor should recognize that the stock's exposure to broader market moves is at market-level beta, but the rating treats its macro fit as weak.
  • Forensic Balance Sheet: 10 / 20. The source cites Altman Z of 2.5, Piotroski F of 2/9, and Debt/Equity of 0.5. The Piotroski reading of 2/9 is weak, and the Altman Z sits in the range the rating methodology treats as a moderate-stress signal.

Investor implications: the upside case rests on a balance sheet and cash position that the source shows to be small relative to recent annual losses, and any recovery would need to come from operating improvement that the financials do not yet show. Valuation tradeoffs are difficult to assess because earnings-based multiples are not available in the source data. The price of $1.57 sits near the bottom of a 52-week range of $1.36 to $64.12, which means the stock has already declined sharply, and the market capitalization of $3.4M indicates a very small equity value. Second-order risk includes the liquidity and volatility implications of a micro-cap with limited trading volume (23,073 shares). This is an analytical summary of the rating, not personalized financial advice.

Business

GRI Bio Inc. (GRI) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the profile). The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M in each of the listed periods (per the SEC financials), indicating no revenue recognized in the source data. Not available in source data for how the company makes money.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-12.0M$-12.0MN/A$-10.2M$8.2MN/A
FY 2024$0.0M$-8.2M$-8.2MN/A$-8.6M$5.0MN/A
FY 2023$0.0M$-11.4M$-13.0MN/A$-9.0MN/AN/A

Per the SEC financials, the company reported operating losses in each period, with FY 2025 net loss of $-12.0M and free cash flow of $-10.2M. Gross, operating, and net margins are each listed as 0% (per the market data), consistent with no revenue. ROIC is -35% (per the market data). The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity of 0.5 (per the Roarable RQD rating). Cash rose from $5.0M in FY 2024 to $8.2M in FY 2025 (per the SEC financials), and the source does not provide a debt figure for any period.

Recent Catalysts & News Wire Analysis

Per the news wire, the headlines in the source are primarily market-wire and aggregator items referencing GRI with no substantive company-specific detail. Items include a TradingView estimates report, a Yahoo! Finance Canada quote page, a kalkine.ca item describing an intraday decline of 16.48% to about USD 0.79, a Yahoo Finance item on a reverse split, and TradingKey gainers and losers lists. The reverse split item references Revelation Biosciences, a different company name, and should be treated as unverified for GRI. The catalyst-flagged item is the TradingKey gainers list (light: GREEN); the remaining items are market-wire (light: YELLOW). Risk watch items are the reported intraday decline and the 52-week range.

Butterfly signal: the Butterfly Supply-Chain Graph assigns a LIQUIDITY_TAILWIND signal with a severity score of 94 and direction BEARISH. It reports a Macro Tailwind Score of 20/100, a rolling 5-year Net Liquidity beta of 3.34x with correlation of +0.17, Net Liquidity of $5,745.73B with a -0.64% 4-week rate of change, and High-Yield OAS of +2 bps. Per the graph, the signal characterizes GRI as highly sensitive to liquidity conditions.

Open Questions

  • What is the company's product pipeline and revenue path, given zero reported revenue across the source periods?
  • What is the current debt position, since the source lists debt as N/A for all periods?
  • What cash runway exists relative to the reported annual free cash flow losses?
  • Which insider, institutional, or Congressional transactions have occurred, given that the holders section is empty?
  • Does the reverse split referenced in the news wire relate to GRI, given that the headline names a different company?

GRI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for GRI Bio Inc. (GRI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GRI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GRI Bull vs. Bear Conversation Board — What's Your Call at $1.53?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GRI 🐻 67% BEARISH CONVICTION
1. Pick Your Side on GRI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.38 (-12.1%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is GRI (D- • RQD 37/100) a Buy at $1.57?

Welcome to the GRI (GRI Bio Inc.) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.19 (-24.2%)
Spot @ $1.57

Pump the brakes on GRI — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on GRI, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless GRI Bio Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.92 (+22.3%)
Spot @ $1.57

GRI cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on GRI, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.57 (52-wk range $1.36 - $64.12), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%